136 Shares in ICON Public Limited (NASDAQ:ICLR) Acquired by Sierra Ocean LLC

Sierra Ocean LLC purchased a new position in shares of ICON Public Limited (NASDAQ:ICLR) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 136 shares of the medical research company’s stock, valued at approximately $29,000.

A number of other large investors have also recently made changes to their positions in ICLR. Foyston Gordon & Payne Inc bought a new stake in shares of ICON Public in the 3rd quarter worth approximately $11,672,000. Icon Wealth Advisors LLC grew its position in shares of ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares during the last quarter. Entropy Technologies LP grew its position in shares of ICON Public by 472.2% in the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after buying an additional 5,095 shares during the last quarter. Tributary Capital Management LLC grew its position in shares of ICON Public by 116.1% in the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock worth $828,000 after buying an additional 2,122 shares during the last quarter. Finally, Whittier Trust Co. grew its position in shares of ICON Public by 12.3% in the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after buying an additional 441 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Price Performance

NASDAQ:ICLR opened at $188.65 on Wednesday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $15.56 billion, a P/E ratio of 21.03, a P/E/G ratio of 1.78 and a beta of 1.19. ICON Public Limited has a 12 month low of $181.51 and a 12 month high of $347.72. The business’s 50-day moving average is $203.63 and its 200 day moving average is $246.83.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ICLR. William Blair restated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Baird R W cut ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. JPMorgan Chase & Co. decreased their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Citigroup decreased their price target on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $255.00 price objective (down previously from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $283.92.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.